Beijing Pason Pharmaceuticals, Inc. (Pason): developing and commercializing Triapine® in China, Hong Kong, Taiwan and Macao (the Territory) for anticancer and antiviral applications.

Pason has licensed our product Triapine® for anticancer and antiviral applications in the Territory. Pason is funding the development of Triapine® in the Territory and Vion could receive potential milestone payments and royalties based on sales in the Territory.

B&P Company, Inc.: license agreement for Melasyn®, our synthetic melanin.

Vion has entered into a non-exclusive sublicense agreement for our synthetic melanin technology with B&P Company, Inc. Melanin is a pigment formed by cells in the skin that gives skin its color and protects it from sun damage by absorbing ultraviolet rays. Melasyn® is a synthetic form of melanin that dissolves readily in water. The terms of the agreement do not include any upfront or milestone payments. If products including our technology are developed, we will receive a royalty based on sales in countries where we have issued patents.

Achillion Pharmaceuticals, Inc.: developing and commercializing Vion’s antiviral technology

Achillion Pharmaceuticals, Inc. has licensed our antiviral technology ß-L-Fd4C, a potential treatment for Hepatitis-B (HBV) and HIV.

Achillion is funding the development of ß-L-Fd4C, which it plans to develop as one of its leading product candidates. Vion may receive potential milestone payments and downstream royalties if ß-L-Fd4C is successfully developed. Vion also owns an equity position in Achillion.